Cargando…

Harnessing tumorous flaws for immune supremacy: is miRNA-155 the weak link in breast cancer progression?

With the advent of immune checkpoint blockade (ICB) therapy, treatment strategies for late-stage cancers have seen a radical advancement. In this issue of the JCI, Wang et al. characterize the functional role of miR-155 in breast cancer and its potential in harnessing the efficacy of immunotherapy....

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Samantha, Opyrchal, Mateusz, Lu, Xiongbin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9525109/
https://www.ncbi.nlm.nih.gov/pubmed/36189796
http://dx.doi.org/10.1172/JCI163010
_version_ 1784800637424238592
author Sharma, Samantha
Opyrchal, Mateusz
Lu, Xiongbin
author_facet Sharma, Samantha
Opyrchal, Mateusz
Lu, Xiongbin
author_sort Sharma, Samantha
collection PubMed
description With the advent of immune checkpoint blockade (ICB) therapy, treatment strategies for late-stage cancers have seen a radical advancement. In this issue of the JCI, Wang et al. characterize the functional role of miR-155 in breast cancer and its potential in harnessing the efficacy of immunotherapy. The study reports that high expression levels of miR-155 in breast cancer cells downregulated suppressor of cytokine signaling 1 (SOCS1), increased the phosphorylated STAT1 (pSTAT1)/pSTAT3 ratio, and thereby stimulated chemoattractants for tumor infiltration of effector T cells. Moreover, miR-155 overexpression set the stage for ICB therapy via increased programmed death ligand 1 (PD-L1) expression on cancer cells and enhanced immunological memory response via the release of miR-155–containing extracellular vesicles. Collectively, these data suggest that miR-155 is a strong candidate as a prognostic biomarker for ICB therapy.
format Online
Article
Text
id pubmed-9525109
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Society for Clinical Investigation
record_format MEDLINE/PubMed
spelling pubmed-95251092022-10-05 Harnessing tumorous flaws for immune supremacy: is miRNA-155 the weak link in breast cancer progression? Sharma, Samantha Opyrchal, Mateusz Lu, Xiongbin J Clin Invest Commentary With the advent of immune checkpoint blockade (ICB) therapy, treatment strategies for late-stage cancers have seen a radical advancement. In this issue of the JCI, Wang et al. characterize the functional role of miR-155 in breast cancer and its potential in harnessing the efficacy of immunotherapy. The study reports that high expression levels of miR-155 in breast cancer cells downregulated suppressor of cytokine signaling 1 (SOCS1), increased the phosphorylated STAT1 (pSTAT1)/pSTAT3 ratio, and thereby stimulated chemoattractants for tumor infiltration of effector T cells. Moreover, miR-155 overexpression set the stage for ICB therapy via increased programmed death ligand 1 (PD-L1) expression on cancer cells and enhanced immunological memory response via the release of miR-155–containing extracellular vesicles. Collectively, these data suggest that miR-155 is a strong candidate as a prognostic biomarker for ICB therapy. American Society for Clinical Investigation 2022-10-03 /pmc/articles/PMC9525109/ /pubmed/36189796 http://dx.doi.org/10.1172/JCI163010 Text en © 2022 Sharma et al. https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Commentary
Sharma, Samantha
Opyrchal, Mateusz
Lu, Xiongbin
Harnessing tumorous flaws for immune supremacy: is miRNA-155 the weak link in breast cancer progression?
title Harnessing tumorous flaws for immune supremacy: is miRNA-155 the weak link in breast cancer progression?
title_full Harnessing tumorous flaws for immune supremacy: is miRNA-155 the weak link in breast cancer progression?
title_fullStr Harnessing tumorous flaws for immune supremacy: is miRNA-155 the weak link in breast cancer progression?
title_full_unstemmed Harnessing tumorous flaws for immune supremacy: is miRNA-155 the weak link in breast cancer progression?
title_short Harnessing tumorous flaws for immune supremacy: is miRNA-155 the weak link in breast cancer progression?
title_sort harnessing tumorous flaws for immune supremacy: is mirna-155 the weak link in breast cancer progression?
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9525109/
https://www.ncbi.nlm.nih.gov/pubmed/36189796
http://dx.doi.org/10.1172/JCI163010
work_keys_str_mv AT sharmasamantha harnessingtumorousflawsforimmunesupremacyismirna155theweaklinkinbreastcancerprogression
AT opyrchalmateusz harnessingtumorousflawsforimmunesupremacyismirna155theweaklinkinbreastcancerprogression
AT luxiongbin harnessingtumorousflawsforimmunesupremacyismirna155theweaklinkinbreastcancerprogression